

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
GRANT AGREEMENT OF RECOMBINANT POLIOMYELITIS
VACCINE AND RELATED COMBINED VACCINE PROJECT

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated October 24, 2023 in relation to a grant agreement entered into by the Group and the Bill & Melinda Gates Foundation (the “**foundation**”). The Company is pleased to announce that as the research and development of the Recombinant Poliomyelitis Vaccine (“**CS-2036**”), a polio vaccine candidate based on virus-like particle (“**VLP**”) of the Company (“**Project CS-2036**”), continues to advance, the Company has entered into a new grant agreement with the foundation, pursuant to which with the mutually agreed request, the Company will receive over US\$17 million in total to support the further development of the CS-2036 candidate, including clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidates. The payments are subject to, among others, the payment schedule associated with the completion of various development targets/milestones.

Based on the protein structure design and VLP assembly technology of the Company, CS-2036 candidate is a non-infectious polio VLP vaccine with good safety and immunogenicity profiles that does not rely on live virus in the manufacturing process. Non-infectious polio VLP-based vaccines are recommended by the World Health Organization as one of the preferred vaccines for polio in the future expected to be an ideal post-eradication polio vaccine. The CS-2036 candidate can also be a component of combined vaccines, which will facilitate broader dissemination to aid in the eradication of polio.

To achieve the accessibility and affordability of polio vaccines in developing or underdeveloped countries, the Company will ensure that the knowledge and information gained from Project CS-2036 will be promptly and broadly disseminated and the funded developments will be made available and accessible at an affordable price to people most in need within developing countries.

We cannot guarantee that we will ultimately develop or commercialize CS-2036 candidate and/or CS-2036 component combined vaccine candidates successfully. Considering several unpredictable factors in the process of clinical trials and the results and timing of clinical trials, evaluations and approvals are subject to uncertainty. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, October 9, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.